Keywords: sanofi-synthelabo, pentasaccharide, shows, superiority, over, lovenox, long-awaited

Sanofi-Synthelabo's pentasaccharide shows superiority over Lovenox

Article | 31 August 2000

Print This

The long-awaited data from a Phase IIb dose-ranging study ofOrganon/Sanofi-Synthelabo's pentasaccharide Org31540/SR9-0107A show that it is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in